Polymedix

Saturday, February 26, 2011

Why PMX-30063 will revolutinize?

›
Conventional antibiotics generally must enter the bacterial cell to interact with their biochemical target. Bacteria generally can develop...
1 comment:
Saturday, February 12, 2011

Bacterial resistance to the PMX molecules by Falconer66a

›
Frankly, the PolyMedix PMX molecules are simply resistance proof. In order for a bacterium to gain resistance it would have to evolve an e...

PMX 60056 by Falconer66a

›
Once PMX 60056 gets FDA approval, the entire surgical bleeding phenomenon changes. Yes, PMX 60056 just utterly stops or reverses the anti-c...

Polymedix -vs- Tetraphase

›
Post from Falconer66a: They (Tetraphase's compounds) are tetracycline-based. Their difference is that the company is able to synthesi...
Home
View web version

About PolyMedix,

PolyMedix
PolyMedix’s lead antibiotic compound, PMX-30063, is currently in Phase 2 clinical trials. PMX-30063 is a small-molecule that mimics the mechanism of action of human host defense proteins, a mechanism that is distinct from currently approved antibiotic drugs and is intended to make bacterial resistance unlikely to develop. PolyMedix plans to develop this compound for serious systemic Staphylococcal infections, including MRSA. PolyMedix’s lead heptagonist compound, PMX-60056, is currently in Phase 2 clinical trials. and is being developed to reverse the anticoagulant activity of both heparin and low molecular weight heparins (LMWH). PolyMedix believes that PMX-60056 could potentially be a safer and easier to use anticoagulant reversing agent, with broader activity, than the currently approved therapy for reversing heparin and LMWH. In addition to its small molecule therapeutics, PolyMedix has polymeric formulations with the same mechanism of action as PMX-30063, PolyCides™. PolyCides are intended for use in antimicrobial biomaterials applications as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces.
View my complete profile
Powered by Blogger.